| scholarly article | Q13442814 |
| P2093 | author name string | Jun-Ling Li | |
| Zi-Yi Xu | |||
| P2860 | cites work | Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations | Q21132357 |
| A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). | Q47667888 | ||
| Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats | Q47745480 | ||
| Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial | Q47773490 | ||
| An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib | Q47872073 | ||
| Significant drug interaction: phenytoin toxicity due to erlotinib | Q48229241 | ||
| First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung | Q48476437 | ||
| Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. | Q48589806 | ||
| Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity | Q48615207 | ||
| Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics | Q48695639 | ||
| The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. | Q49602341 | ||
| Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction | Q49786703 | ||
| Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. | Q51808302 | ||
| Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer | Q51936030 | ||
| Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure | Q53519220 | ||
| Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study | Q54261327 | ||
| Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors | Q54377793 | ||
| The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects | Q54381356 | ||
| The ERBB network: at last, cancer therapy meets systems biology. | Q54498075 | ||
| Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers | Q54540504 | ||
| Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer | Q54587349 | ||
| Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor | Q55022087 | ||
| Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations | Q55027058 | ||
| Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. | Q55080883 | ||
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57051777 | ||
| Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia | Q73171655 | ||
| Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors | Q79451540 | ||
| Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer | Q80249413 | ||
| Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) | Q82615461 | ||
| Effects of smoking on the pharmacokinetics of erlotinib | Q83143258 | ||
| Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases | Q86036741 | ||
| Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir | Q87050897 | ||
| Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patients | Q90022641 | ||
| Applications of CYP450 testing in the clinical setting | Q24621760 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives | Q27014117 | ||
| Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC | Q27025970 | ||
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) | Q27685359 | ||
| Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors | Q27851633 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Q27852787 | ||
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer | Q27853013 | ||
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Q27853120 | ||
| AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Q27853158 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases | Q28071266 | ||
| Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors | Q28087435 | ||
| The ErbB/HER family of protein-tyrosine kinases and cancer | Q28302611 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | Q31160116 | ||
| Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases | Q33574627 | ||
| New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib | Q33704088 | ||
| Pharmacogenomics: translating functional genomics into rational therapeutics | Q33751829 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants | Q34125166 | ||
| Impact of drug transporter studies on drug discovery and development | Q34215229 | ||
| Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. | Q34260686 | ||
| Effects of Tobacco Smoking and Nicotine on Cancer Treatment | Q34303604 | ||
| Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen | Q34451318 | ||
| Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol | Q34452644 | ||
| Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation | Q34472367 | ||
| Update on epidermal growth factor receptor mutations in non-small cell lung cancer | Q34594740 | ||
| Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance | Q40050525 | ||
| Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. | Q40168706 | ||
| Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 | ||
| Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients. | Q40453635 | ||
| Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice | Q40502617 | ||
| Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling | Q41104952 | ||
| Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015. | Q42019776 | ||
| Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers | Q42106492 | ||
| Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors | Q42781680 | ||
| Elevated international normalized ratio associated with concomitant warfarin and erlotinib | Q42933546 | ||
| Effect of gefitinib on warfarin antithrombotic activity | Q43286571 | ||
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
| United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets | Q44772598 | ||
| Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1. | Q44931908 | ||
| Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. | Q45977770 | ||
| Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. | Q46229939 | ||
| Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. | Q46375109 | ||
| Cytochrome P450-dependent metabolism of gefitinib | Q46402129 | ||
| Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice | Q46413821 | ||
| Drug interaction between complementary herbal medicines and gefitinib | Q46452671 | ||
| Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin | Q46466772 | ||
| Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers | Q46871053 | ||
| Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial | Q47257690 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer | Q47450132 | ||
| The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. | Q47642602 | ||
| Clinical pharmacokinetics of tyrosine kinase inhibitors | Q34611569 | ||
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects | Q34713638 | ||
| Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay | Q34762839 | ||
| Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance | Q35642041 | ||
| Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib | Q35807946 | ||
| Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity | Q35922156 | ||
| Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies | Q36205327 | ||
| Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases | Q36353657 | ||
| Pharmacogenomics and individualized drug therapy | Q36366823 | ||
| Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers | Q37155636 | ||
| The biological and clinical role of drug transporters at the intestinal barrier | Q37318372 | ||
| Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors | Q37369825 | ||
| Clinical Pharmacokinetics and Pharmacodynamics of Afatinib | Q37650711 | ||
| EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. | Q37709182 | ||
| Cytochrome P450 variations in different ethnic populations | Q37979866 | ||
| Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? | Q38022125 | ||
| Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives | Q38101884 | ||
| Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer | Q38148969 | ||
| Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies | Q38168795 | ||
| Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer | Q38179266 | ||
| Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective | Q38225680 | ||
| Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions | Q38229948 | ||
| Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer | Q38253338 | ||
| Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors | Q38335360 | ||
| Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer | Q38352862 | ||
| Targeted therapy for non-small cell lung cancer: current standards and the promise of the future | Q38390200 | ||
| First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study | Q38536391 | ||
| Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer | Q38742732 | ||
| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial | Q38809376 | ||
| Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options | Q39013343 | ||
| Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia | Q39033152 | ||
| Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer | Q39069017 | ||
| Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line | Q39114552 | ||
| Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. | Q39198033 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug interaction | Q718753 |
| P304 | page(s) | 5467-5484 | |
| P577 | publication date | 2019-07-09 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer | |
| P478 | volume | 12 |
| Q90398831 | Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study | cites work | P2860 |
Search more.